EQS-News

DarioHealth Corp. (NASDAQ: DRIO) Prominently Positioned for Digital Therapeutics Consolidation

EQS-News: RazorPitch/DRIO DarioHealth Corp. (NASDAQ: DRIO) Prominently Positioned for Digital Therapeutics Consolidation 21.12.2022 / 11:00 CET/CEST The issuer is solely responsible for the content of this announcement. Article Highlights

• Transition to valued-based healthcare is driving consolidation in digital therapeutics.

• Dario’s clinically verified ROI to payors is lowering costs for the national healthcare sector.

• What is $162 billion in annual savings worth to the healthcare industry?

DarioHealth Corp. (NASDAQ: DRIO) is adding contracts with self-insured employers and national health plans as Amazon and CVS vie to lead value-based, patient-centric virtual healthcare.

Digital healthcare is resulting not only in better health outcomes, but also in lower costs for the national health-care sector. Dario’s user-centric multi-chronic condition platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health, providing a turn-key, one-vendor solution for payers.

As Dario continues to win RFPs with the company's full suite of chronic condition management solutions to help improve overall health, the company recently noted that a new “jumbo” global employer account represents increasing penetration of the Dario platform.

The global company's adoption comes after Dario demonstrated the advantages of its single, seamless experience to improve health and outcomes in a several-month pilot and exemplifies Dario's ability to penetrate some of the largest self-insured employers.

The pilot program verified previous clinical studies that resulted in a 1.4-point drop in A1c among diabetic members for a $60/month fee. Based on the industry's statistical savings of $140 per month per member on a 1 point drop in A1c, Dario could save the healthcare industry $1,632 for each of the 34 million diabetics in the US alone, or a total of $56 billion annually. Including the full suite of chronic conditions, clinical studies indicate a potential $162 billion in annual savings.